Iterion Therapeutics is attending the Oncology & Immunology Innovation Partnering & Licensing Summit in Boston next week.

Iterion Therapeutics is a clinical-stage biotechnology company developing novel small-molecule therapies that target the Wnt/β-catenin signaling pathway—one of the most validated, yet historically “undruggable,” oncogenic drivers. Our lead asset, Tegavivint, is a first-in-class inhibitor of TBL1 (Transducin β-like protein 1), a critical transcriptional co-activator of Wnt/β-catenin. Tegavivint treatment results in degradation of nuclear β-catenin and inhibition of Wnt-activated oncogenic transcription, offering a differentiated safety and efficacy profile versus prior approaches. Tegavivint has demonstrated encouraging anti-tumor activity and durable disease control in clinical studies, including patients with hepatocellular carcinoma (HCC) and desmoid tumors. Iterion is currently advancing Tegavivint in a Phase 2 clinical program in HCC and exploring expansion opportunities in other Wnt-driven cancers with high unmet need. Supported by leading investors and strategic partners, Iterion’s mission is to unlock the therapeutic potential of Wnt/β-catenin inhibition to deliver first-in-class targeted therapies for patients with aggressive cancers.